BioSpace News Archive

According to Nova one advisor, the global Molecular Quality Controls market was valued at USD 184.62 million in 2021 and it is expected to hit around USD 472.64 million by 2030 with a CAGR of 12.4% during the forecast period 2022 to 2030.

Oncopeptides AB announces that the US Food and Drug Administration, has published the Briefing Book for the Oncologic Drugs Advisory Committee meeting on September 22, 2022.

Infixion Bioscience, a pre-clinical drug discovery company focused on developing gene-targeted therapeutics for the rare genetic disorder Neurofibromatosis Type 1 (NF1), announced today the awarding of its third NIH SBIR Phase 1 grant from the National Institute of Neurological Disorders and Stroke (NINDS).

SiSaf Ltd, an RNA delivery and therapeutics company, is pleased to announce its autumn conference schedule for September and October.

HTG Molecular Diagnostics, Inc. announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain, with its partners, the Fundación Pública Andaluza Progreso y Salud and the Centro de Investigación Biomédica en Red, have developed a laboratory-developed test for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that data from multiple studies of LUPKYNIS® (voclosporin), used to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), will be presented at American College of Rheumatology (ACR) Convergence 2022.

Aditxt, Inc announced the closing of its previously announced public offering of 3,333,333 shares of its common stock, together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share and associated warrant.

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced that it will host an investor event on October 5, 2022 to discuss Mia Femtech®.

Twist Bioscience (Nasdaq: TWST) and the Australian Research Council (ARC) Centre of Excellence in Synthetic Biology (CoESB) today announced a partnership that will enable CoESB members and partners to order a wide range of Twist products that facilitate research and development.